Method evidence record

Bayesian Phase I clinical trial

A Bayesian Phase I clinical trial uses prior probability models and sequential Bayes updating to find the maximum tolerated dose (MTD) of a new agent. Unlike the traditional 3+3 rule-based escalation, the Bayesian approach revises a dose-toxicity curve continuously as each patient's outcome is observed, allowing faster convergence to the true MTD while minimising exposure of patients to unsafe or subtherapeutic doses.

Sources recorded, not reviewed

Source record

Citations copied verbatim from the method’s source record. No claim-level verification is inferred from them.

Bayesian Phase I Clinical Trial (Dose-Finding Design)

Taxonomic method record · process-pipeline / epidemiology

O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48. · DOI 10.2307/2531628
Chevret, S. (Ed.). (2006). Statistical Methods for Dose-Finding Experiments. Wiley. · ISBN 978-0470861769

Open full method

Curated claims

Claims persisted in the evidence ledger, each with its own assessment.

No curated claims yet

This view does not invent a claim assessment when the ledger has none.

Related methods

Generated from the method graph and shown as machine-suggested relations — no evidence claim is inferred.

Taxonomic bucketAdaptive Phase I Clinical Trialmachine-suggested · Relational suggestion, not evidence.Taxonomic bucketAdaptive Randomized Clinical Trialmachine-suggested · Relational suggestion, not evidence.Taxonomic bucketBayesian Randomized Clinical Trialmachine-suggested · Relational suggestion, not evidence.Taxonomic bucketDose-Response Analysismachine-suggested · Relational suggestion, not evidence.Taxonomic bucketPhase I Clinical Trialmachine-suggested · Relational suggestion, not evidence.